Tapan Kadia
塔潘·卡迪亚
MD
Professor, Department of Leukemia白血病科教授
👥Biography 个人简介
Innovative clinician-scientist at MD Anderson focused on high-risk AML, particularly TP53-mutant disease. He developed the CLIA regimen and investigates novel induction strategies to improve outcomes in biologically adverse AML subgroups with historically poor prognoses.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
TP53-Mutant AML Treatment
Developed and evaluated novel therapeutic combinations for TP53-mutant AML, a subgroup with dismal outcomes, identifying regimens that achieve responses beyond standard decitabine monotherapy.
Cladribine-Based Induction Regimens
Developed and refined the CLIA (cladribine, idarubicin, cytarabine) regimen, demonstrating superior remission rates compared to standard 7+3 induction in newly diagnosed AML.
Representative Works 代表性著作
Cladribine and low-dose cytarabine alternating with 5-azacitidine and venetoclax in TP53-mutated AML
Lancet Haematology (2021)
Demonstrated meaningful response rates in TP53-mutant AML with a novel regimen, offering a promising platform for a historically treatment-refractory disease subset.
Idarubicin and cladribine with cytarabine compared with 7+3 in frontline AML
Blood (2015)
Phase II trial showing CLIA regimen achieves higher complete remission rates than standard induction, supporting wider adoption and further optimization studies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Naval Daver
The University of Texas MD Anderson Cancer Center
Courtney DiNardo
The University of Texas MD Anderson Cancer Center
关注 塔潘·卡迪亚 的研究动态
Follow Tapan Kadia's research updates
留下邮箱，当我们发布与 Tapan Kadia（The University of Texas MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment